The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...

Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.

Interval breast cancer rates have remained consistent over 30 years despite age-based screening, highlighting the need for ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

BC, OCN, explained that comprehensive disease and treatment education are essential to adherence for patients with breast ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

A real-world study reveals the need for increased homologous repair deficiency and BRCA1/2 testing in patients with ovarian ...